Febit Restructures to Concentrate on miRNA Biomarkers | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Febit today announced it is restructuring its business "as a consequence of its strategic focus on blood-based microRNA biomarker discovery."

As a result, CEO and President Cord Staehler has resigned and joined Siemens Healthcare. Hartmut Voss has joined the company as co-CEO. Jochen Kohlhaas is the other co-CEO and will continue as the company's chief financial officer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.